The content you are trying to access is intended
for healthcare professionals only. 


Are you a healthcare professional?
The content you are about to view is intended for healthcare professionals. You are being redirected.
The content you are about to view is intended for consumers. You are being redirected.

A major innovation in the dietary management of glycogen storage disease (GSD)

Glycosade-timeline

Glycosade Timeline

2007: A novel starch for the treatment of glycogen storage diseases
A novel starch for the treatment of glycogen storage diseases

Bhattacharya K, Orton RC, Qi X, et al. A novel starch for the treatment of glycogen storage diseases. J Inherit Metab Dis. 2007; 30 (3): 350-357.

moments
2008: Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib
Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib

Correia CE, Bhattacharya K, Lee PJ, et al. Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib. Am J Clin Nutr. 2008; 88(5): 1272-1276.

moments
2009: The use of Glycosade to extend fasting tolerance and improve oral intake in GSD1b
The use of Glycosade to extend fasting tolerance and improve oral intake in GSD1b

Humphrey MS. The use of Glycosade to extend fasting tolerance and improve oral intake in GSD1b. Mol Genet Metab. 2009; 98: 89-118. CLOSED ACCESS
2009: Reduction in insulin response in a patient with GSD1 using a new modified starch
Reduction in insulin response in a patient with GSD1 using a new modified starch

Maritz CM, Cousins A, Murphy E. Reduction in insulin response in a patient with GSD1 using a new modified starch: Case report. Mol Genet Metab.2009; 98: 39-88.
2010: Using a Modified Cornstarch in the Management of Glycogen Storage Disease.
Using a Modified Cornstarch in the Management of Glycogen Storage Disease.

Mullally M, Eardley J, Gick J, Mundy H, Champion M. Retrospective evaluation of clinical practice: using a modified cornstarch in the management of glycogen storage disease. J Inherit Metab Dis. 2010; 33 (suppl 1): S1-S197.

moments
2013: Assessment of Safety and Efficacy of Extended Release Cornstarch Therapy in Glycogen Storage Disease Type Ia
Assessment of Safety and Efficacy of Extended Release Cornstarch Therapy in Glycogen Storage Disease Type Ia

Corrado MM, Ross KM, Brown LM, Correia CE, Weinstein DA. Assessment of safety and efficacy of extended release cornstarch therapy in glycogen storage disease type Ia. J Inherit Metab Dis. (2013); 36 (suppl 2): S5227-S5228.

momentsmoments
2013: Comparison of Glycosade and uncooked cornstarch (UCCS) for the treatment of glycogen storage disease type I (GSDI)
Comparison of Glycosade and uncooked cornstarch (UCCS) for the treatment of glycogen storage disease type I (GSDI)

Hubert-Buron A, Mollet-Boudjemline A, Voillot C, et al. Comparison of Glycosade and uncooked cornstarch (UCCS) for the treatment of hepatic glycogen storage disease type I (GSD I). Poster presented at IGSD, Heidelberg (2013).

moments
2013: Nutrition in Glycogen Storage Disease Lecture
Nutrition in Glycogen Storage Disease Lecture

Vitaflo is pleased to bring you the following lecture presentations which were recorded at the 1st Nutrition in Glycogen Storage Disease (GSD) Education Day held in Raleigh-Durham, North Carolina on September 19th, 2013. This one-day educational program for dietitians and other healthcare professionals included discussions on the nutritional management of GSD types I and III, current guidelines and practices for management using uncooked corn starch and Glycosade (Vitaflo®), as well as a review of the needs for protein in GSD type III.

Watch Lecture Here
2015: A pilot longitudinal study of the use of waxy maize heat modified starch in the treatment of adults with glycogen storage disease type I: a randomized double-blind cross-over study.
A pilot longitudinal study of the use of waxy maize heat modified starch in the treatment of adults with glycogen storage disease type I: a randomized double-blind cross-over study.

Bhattacharya K, Mundy H, Lilburn MF, Champion MP, Morley DW, Maillot F. A pilot longitudinal study of the use of waxy maize heat modified starch in the treatment of adults with glycogen storage disease type I: a randomized double-blind cross-over study. Orphanet J Rare Dis. 2015; 10 (1): 18.

moments
2015: Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type I.
Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type I.

Ross KM, Brown LM, Corrado MM, Chengsupanimit T, Curry LM, Ferrecchia IA, Porras LY, Mathew JT, Weinstein DA. Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type I. JIMD Rep. 2015 Aug 25. [Epub ahead of print]

Learn More Here
2016: Safety and Efficacy of Long-Term Use of Extended Release Cornstarch Therapy for Glycogen Storage Disease Types 0, III, VI, and IX.
Safety and Efficacy of Long-Term Use of Extended Release Cornstarch Therapy for Glycogen Storage Disease Types 0, III, VI, and IX.

Ross KM, Brown LM, Corrado MM, Chengsupanimit T, Curry LM, Ferrecchia IA, Porras LY, Mathew JT, Dambska M, and Weinstein DA. Safety and Efficacy of Long-Term Use of Extended Release Cornstarch Therapy for Glycogen Storage Disease Types 0, III, VI, and IX. Jour Nutr Ther. 2016;4:137-142.

Learn More Here
formula4success

Medical foods intended for use under medical supervision.

Vitaflo, Glycosade and the GoGlycosade logo are trademarks of Société des produits Nestlé S.A., Vevey, Switzerland.